{"meta":{"query_hash":"c98e8d888c40","filters":{"venue":"Future Rare Diseases"},"cohort_total":19,"direct_labels_cover":0,"predictions_cover":19,"exported":19,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c98e8d888c40","api":"https://metacan.xera.ac/api/v1/cohort?venue=Future+Rare+Diseases"},"results":[{"id":"W3128891271","doi":"10.2217/frd-2020-0006","title":"Transfusion of Modified Blood Components for the Treatment of Autoimmune Hemolytic Anemia: A Network Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Blood groups and transfusion","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Autoimmune hemolytic anemia; Adverse effect; Anemia; Randomized controlled trial; Internal medicine; Immunology; Hemoglobin; Hemolytic anemia; Meta-analysis","score_opus":0.041170669707332005,"score_gpt":0.2736758022095728,"score_spread":0.2325051325022408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128891271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78340584,0.20885137,0.0019090947,0.002812012,0.0002703495,0.0015012306,0.0011134433,0.00004570548,0.00009094409],"genre_scores_gemma":[0.9943702,0.0037556463,0.00044237656,0.0001082687,0.00026254775,0.00011607931,0.00075827976,0.00001976984,0.00016682134],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9987681,0.000065089574,0.00040160093,0.00028206574,0.00029198776,0.0001911547],"domain_scores_gemma":[0.998796,0.00024678913,0.00011645174,0.00056173105,0.00018292971,0.00009609921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055595083,0.00020769922,0.0012312409,0.000060253635,0.000114566275,0.0000074623367,0.00008233671,0.00009182613,0.00030295554],"category_scores_gemma":[0.000008255692,0.00011526422,0.0024361776,0.0005730365,0.000051477848,0.000025540274,0.000009232617,0.00005587602,3.7255484e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008267432,0.032425504,0.034076303,0.0032556998,0.8482531,0.00057077536,0.0031588022,0.008882517,0.03135699,0.0015050176,0.0009757206,0.027272178],"study_design_scores_gemma":[0.005755915,0.00084519316,0.091078214,0.00003490456,0.8908886,0.000018216268,0.00036162784,0.0010029915,0.0076173046,0.00010325364,0.0021363993,0.00015738273],"about_ca_topic_score_codex":0.00010704963,"about_ca_topic_score_gemma":0.00006906173,"teacher_disagreement_score":0.21096435,"about_ca_system_score_codex":0.000013872918,"about_ca_system_score_gemma":0.00008614662,"threshold_uncertainty_score":0.47003385},"labels":[],"label_agreement":null},{"id":"W4317212031","doi":"10.2217/frd-2022-0015","title":"The Effects of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva: A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; UCB Pharma; Incyte; BioCryst; Mead Johnson Nutrition; International Fibrodysplasia Ossificans Progressiva Association; Ultragenyx Pharmaceutical; Ipsen; Regeneron Pharmaceuticals; Pfizer","keywords":"Fibrodysplasia ossificans progressiva; Clinical trial; Medicine; Heterotopic bone; Myositis ossificans; Physical therapy; Bone formation; Dentistry; Surgery; Heterotopic ossification; Internal medicine","score_opus":0.002490181814365724,"score_gpt":0.22673687399539838,"score_spread":0.22424669218103266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317212031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962214,0.0009076697,0.0000021513865,0.0011795568,0.00019630538,0.0010212059,0.00010957264,0.00010422915,0.00025788622],"genre_scores_gemma":[0.9980898,0.0000734028,0.000019266061,0.00007406747,0.00013333544,0.00019383269,0.0006226239,0.000015853437,0.0007778223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992088,0.000057596833,0.00016424495,0.00015937505,0.00022715791,0.00018284531],"domain_scores_gemma":[0.999335,0.00014745325,0.00006464013,0.00029222463,0.00005323901,0.00010743733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030851024,0.00010473541,0.00015782667,0.000099208904,0.00009816997,0.000013462757,0.00008081952,0.00006795013,0.000025830186],"category_scores_gemma":[0.00011871886,0.00005712542,0.000059627284,0.00044619103,0.00008901479,0.000037295296,0.000016190692,0.00013178303,0.000016204029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006202261,0.0006201103,0.9601692,0.0008029721,0.00018763458,0.00035175047,0.0011939779,0.0000030798928,0.00028191568,0.00030191688,0.010207,0.025260193],"study_design_scores_gemma":[0.0019453324,0.00020576504,0.99306536,0.00047814244,0.00007113966,0.000001500036,0.0006426238,0.000012530005,0.00018082578,0.00001312685,0.00331103,0.00007264669],"about_ca_topic_score_codex":0.0000052076753,"about_ca_topic_score_gemma":0.000008857719,"teacher_disagreement_score":0.032896116,"about_ca_system_score_codex":0.000023096016,"about_ca_system_score_gemma":0.000092840244,"threshold_uncertainty_score":0.2329507},"labels":[],"label_agreement":null},{"id":"W4388536081","doi":"10.2217/frd-2023-0013","title":"Plain language summary of a study looking at whether genetic testing can help doctors diagnose the severity of mucopolysaccharidosis type I (MPS I)","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Mucopolysaccharidosis type I; Enzyme replacement therapy; Phenotype; Missense mutation; Genotype; Gene; Genetics; Mucopolysaccharidosis I; Disease; Genotype-phenotype distinction; Enzyme; Biology; Medicine; Biochemistry; Internal medicine","score_opus":0.020261194488716258,"score_gpt":0.300552782468921,"score_spread":0.2802915879802047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388536081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274707,0.005173384,7.2873144e-7,0.00040154936,0.00018395542,0.000952713,0.00031059256,0.000104282386,0.0001257188],"genre_scores_gemma":[0.9987952,0.00012316904,0.000029348306,0.00010084234,0.0003537944,0.000067438166,0.00009398831,0.000047446687,0.0003887417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809974,0.0002141223,0.00030820863,0.00031969306,0.0007046316,0.00035358043],"domain_scores_gemma":[0.99837047,0.00054283027,0.00013029842,0.0005654843,0.00021659267,0.00017429859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018460413,0.00020048564,0.00038530893,0.00016872562,0.00015375161,0.000014961301,0.00028000292,0.000070143404,0.00034958],"category_scores_gemma":[0.0012257987,0.00013809894,0.00013683653,0.0012357243,0.00012895651,0.000040689523,0.00029384857,0.00018636398,0.000015156051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031207994,0.00053637923,0.97729504,0.00045327286,0.00020127509,0.0005038928,0.0056337225,0.00002045293,0.002146251,0.000002447253,0.0043916423,0.008503552],"study_design_scores_gemma":[0.0010247169,0.00041177706,0.97160107,0.00023165657,0.00027754394,0.0000130068875,0.024402695,0.00009833131,0.0014397562,0.000018483699,0.00031806147,0.0001628781],"about_ca_topic_score_codex":0.0016672716,"about_ca_topic_score_gemma":0.00083786924,"teacher_disagreement_score":0.018768974,"about_ca_system_score_codex":0.000101197904,"about_ca_system_score_gemma":0.00022132047,"threshold_uncertainty_score":0.5631511},"labels":[],"label_agreement":null},{"id":"W4390113708","doi":"10.2217/frd-2023-0022","title":"Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"","keywords":"Hereditary angioedema; Vanguard; Placebo; Medicine; C1-inhibitor; Angioedema; Surgery; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.015851182321688622,"score_gpt":0.29905527407922994,"score_spread":0.2832040917575413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390113708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757013,0.018973386,0.000032269112,0.0014620264,0.00079477363,0.0021318488,0.00069142424,0.000107533924,0.00010548064],"genre_scores_gemma":[0.99612826,0.00006943015,0.00003411773,0.00012702723,0.0011837957,0.00012407509,0.00032629626,0.000031384563,0.0019756032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987499,0.00008962445,0.00033953806,0.00022279785,0.0003935266,0.00020458398],"domain_scores_gemma":[0.9987499,0.00035568626,0.00018381308,0.0005318316,0.00011129437,0.00006746377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018654429,0.00016668238,0.00033116486,0.000079005644,0.00014588125,0.000008896199,0.00021062129,0.0000625908,0.000083294646],"category_scores_gemma":[0.00020016964,0.000095565425,0.00047677656,0.00045408364,0.00008180516,0.0000716224,0.00006154019,0.00006806744,0.0000033847934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002506182,0.0027508626,0.5779334,0.0020383194,0.001751227,0.00013534562,0.018063704,0.00014038003,0.001161487,0.0003873998,0.33848965,0.0546421],"study_design_scores_gemma":[0.002275289,0.00046522747,0.95521396,0.00034887035,0.0010414213,0.00000940174,0.03433704,0.00024943368,0.0008284643,0.00013820261,0.0049544983,0.00013816508],"about_ca_topic_score_codex":0.000060565177,"about_ca_topic_score_gemma":0.00010255007,"teacher_disagreement_score":0.37728065,"about_ca_system_score_codex":0.00002207332,"about_ca_system_score_gemma":0.0001508589,"threshold_uncertainty_score":0.3897045},"labels":[],"label_agreement":null},{"id":"W4391262940","doi":"10.2217/frd-2023-0024","title":"Plain language summary of efanesoctocog alfa for patients with severe hemophilia A","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Clotting factor; Prophylactic treatment; Clinical research; Pediatrics; Surgery; Internal medicine","score_opus":0.006988405016050799,"score_gpt":0.2737567799168182,"score_spread":0.2667683749007674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391262940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806215,0.011550261,0.000007489537,0.0016329873,0.0002551584,0.0021171665,0.0024902555,0.0001528897,0.0011722598],"genre_scores_gemma":[0.99091434,0.000077210476,0.00024329472,0.000115912,0.00090911007,0.00019327816,0.0026449221,0.00004956639,0.0048523527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894637,0.00002211406,0.00014505927,0.00027646383,0.00036214155,0.00024785803],"domain_scores_gemma":[0.99927163,0.00013554598,0.00002418483,0.00024566898,0.00011936939,0.00020362165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000348244,0.00017277602,0.00027271823,0.00012287637,0.000054333676,0.000020312775,0.000076159515,0.00007879046,0.00023870767],"category_scores_gemma":[0.00005047192,0.00010374033,0.00017189256,0.00022781453,0.000058044134,0.000078775956,0.000026403124,0.000098462224,0.000015500827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079676,0.0028661601,0.64694065,0.01165869,0.0015439655,0.0018046388,0.002171077,0.000002721166,0.00031876136,0.00059040077,0.23762499,0.086510375],"study_design_scores_gemma":[0.021214265,0.007353511,0.69516796,0.0062438785,0.0029820462,0.000107255226,0.0047565573,0.00027585067,0.0022659723,0.00052610785,0.25784248,0.0012641347],"about_ca_topic_score_codex":0.000008272888,"about_ca_topic_score_gemma":0.0000057901284,"teacher_disagreement_score":0.08524624,"about_ca_system_score_codex":0.000053032014,"about_ca_system_score_gemma":0.00021958408,"threshold_uncertainty_score":0.42304078},"labels":[],"label_agreement":null},{"id":"W4394716792","doi":"10.2217/frd-2023-0028","title":"The effects of garetosmab in people with fibrodysplasia ossificans progressiva (FOP): A plain language summary of the LUMINA-1 study","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Fibrodysplasia ossificans progressiva; Medicine; Plain language; Anatomy; Linguistics; Heterotopic ossification","score_opus":0.0026192150206411787,"score_gpt":0.24449630671473851,"score_spread":0.24187709169409732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394716792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892534,0.00683678,0.0000026756716,0.0016929441,0.00031781747,0.0016768355,0.00009027654,0.00005036412,0.00040694114],"genre_scores_gemma":[0.99833834,0.000053472875,0.000006879381,0.00003108982,0.00013743051,0.00024876712,0.00004437903,0.000015694395,0.0011239373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990914,0.00012561593,0.00019382699,0.00018385795,0.00026552708,0.00013979008],"domain_scores_gemma":[0.99914443,0.0002519063,0.00006548742,0.00042640493,0.000043355714,0.00006841151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053272586,0.00011864449,0.00019820829,0.00007151212,0.00009085332,0.000022309283,0.00014251014,0.000057336874,0.000035301106],"category_scores_gemma":[0.00010194127,0.000053651747,0.000100181715,0.0004756695,0.00013173623,0.000037245816,0.000026729098,0.00020358569,0.0000022729673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073935423,0.0027816037,0.9193048,0.005051444,0.0008856458,0.0009960324,0.029923782,0.0000056864524,0.0022900817,0.0012207289,0.011055933,0.025744911],"study_design_scores_gemma":[0.0011808532,0.00045143848,0.9770522,0.0017557266,0.00037702007,0.000025442841,0.01519705,0.000044790482,0.00093735254,0.000011283738,0.0028768638,0.000089938454],"about_ca_topic_score_codex":0.00002315006,"about_ca_topic_score_gemma":0.00015437766,"teacher_disagreement_score":0.057747442,"about_ca_system_score_codex":0.00003084768,"about_ca_system_score_gemma":0.00024597367,"threshold_uncertainty_score":0.21878548},"labels":[],"label_agreement":null},{"id":"W4401784358","doi":"10.1080/23995270.2024.2380247","title":"A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; Omeros Corporation; Alexion Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Antibody; Immunology","score_opus":0.0056869594446195175,"score_gpt":0.24344805028455876,"score_spread":0.23776109083993924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401784358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9000318,0.092865095,0.000010199639,0.00072328316,0.00054616656,0.0022145535,0.0035066912,0.000039747447,0.00006246048],"genre_scores_gemma":[0.99673665,0.0012739853,0.000028139135,0.00015347937,0.00073257065,0.00028488724,0.0004026322,0.0000331139,0.00035451888],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990846,0.000047111113,0.00024394973,0.0001946216,0.00027097235,0.00015877419],"domain_scores_gemma":[0.9990649,0.00023259684,0.00009717352,0.00043394603,0.00009233408,0.000079043646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003463883,0.00018513427,0.0003291276,0.000047229598,0.00007623922,0.000021683278,0.000109463115,0.00004455169,0.000065460554],"category_scores_gemma":[0.000049592243,0.0000744242,0.00050277583,0.00021321968,0.00010366819,0.000045785582,0.000019684647,0.000048452686,0.0000016618392],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34070334,0.01013538,0.19903433,0.008187519,0.004881579,0.0002491054,0.010830528,0.00007109137,0.00032659393,0.001168162,0.045928318,0.37848407],"study_design_scores_gemma":[0.03465078,0.006993634,0.83505625,0.0015412617,0.0041627754,0.000004545508,0.0036639231,0.000092599905,0.0005147351,0.000079521094,0.11298304,0.00025694526],"about_ca_topic_score_codex":0.000055176,"about_ca_topic_score_gemma":0.000020270323,"teacher_disagreement_score":0.6360219,"about_ca_system_score_codex":0.000045632587,"about_ca_system_score_gemma":0.00021111495,"threshold_uncertainty_score":0.30349308},"labels":[],"label_agreement":null},{"id":"W4401925418","doi":"10.1080/23995270.2024.2383163","title":"Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Gastroenterology","funders":"","keywords":"Fabry disease; Medicine; Pediatrics; BETA (programming language); Disease; Internal medicine; Computer science","score_opus":0.007470405384718379,"score_gpt":0.2732195483789067,"score_spread":0.26574914299418834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401925418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771959,0.017800648,0.0000051778998,0.0023055614,0.00009658988,0.0010387864,0.0012505773,0.000109558365,0.00019715563],"genre_scores_gemma":[0.9955688,0.0001534639,0.000011936963,0.00020131623,0.00024743052,0.0001505699,0.0012116028,0.00006373889,0.0023911577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817455,0.00011482158,0.0002427524,0.00042112562,0.00064127275,0.00040545536],"domain_scores_gemma":[0.99889433,0.0001477732,0.000044803477,0.00057213625,0.00004580116,0.00029514413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070359776,0.0002869585,0.0004905121,0.00020381586,0.000086388616,0.000056585122,0.00018066687,0.00006668585,0.0005507045],"category_scores_gemma":[0.00007785485,0.00016130785,0.00024153494,0.0004931774,0.00013552018,0.000110343746,0.00010425858,0.00018353607,0.000028048658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083095336,0.00056939124,0.96788555,0.00070679974,0.00039476683,0.010535291,0.006809517,0.000014157617,0.000068764435,0.000080041864,0.0026773764,0.009427415],"study_design_scores_gemma":[0.0018204534,0.00037818516,0.98650646,0.0005793301,0.0004074127,0.000010243049,0.0047239778,0.000120397446,0.000051511197,0.000021898757,0.005204455,0.00017564488],"about_ca_topic_score_codex":0.0005396795,"about_ca_topic_score_gemma":0.0041685263,"teacher_disagreement_score":0.018620966,"about_ca_system_score_codex":0.00038319177,"about_ca_system_score_gemma":0.00032703875,"threshold_uncertainty_score":0.65779436},"labels":[],"label_agreement":null},{"id":"W4406721598","doi":"10.1080/23995270.2024.2444861","title":"The effects of elafibranor in people with primary biliary cholangitis: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nutrition Society; Canadian Paediatric Society; Canadian Cardiovascular Society; University of Calgary","funders":"Ipsen; Astellas Pharma; Fonds Wetenschappelijk Onderzoek; Boston Scientific Corporation; Gilead Sciences; GlaxoSmithKline; U.S. Department of Justice; AstraZeneca; Vlaamse regering; Dr. Falk Pharma; Pfizer; Novo Nordisk","keywords":"Plain language; Medicine; Primary (astronomy); General surgery; Internal medicine; Geography; Linguistics; Physics; Astrophysics; Philosophy","score_opus":0.0014578343983965684,"score_gpt":0.20842116826401139,"score_spread":0.20696333386561483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406721598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9357398,0.060631122,0.0000043749005,0.00066849944,0.00022808049,0.0007111239,0.0001605449,0.00005670524,0.0017997347],"genre_scores_gemma":[0.9960408,0.0010831326,0.000035398203,0.0009851954,0.00020441871,0.00009884866,0.00035131708,0.000019827181,0.0011810247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912006,0.00010933718,0.00016996267,0.00018670103,0.0001978072,0.00021615664],"domain_scores_gemma":[0.99890494,0.0004162318,0.000052026953,0.0004699771,0.000048173217,0.00010867306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052548978,0.00015506479,0.00029843758,0.000108224885,0.0001003331,0.000020428273,0.00015737301,0.00005612064,0.000025584764],"category_scores_gemma":[0.00014342672,0.00009165015,0.00012749352,0.00043961464,0.000081427796,0.000103185215,0.00007315062,0.00016650413,0.0000026273121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002809193,0.00078272243,0.95763695,0.004123078,0.00028553058,0.00038529452,0.00079257315,0.0000010425186,0.0007051231,0.00023717276,0.016155304,0.016086034],"study_design_scores_gemma":[0.0021985888,0.00020297855,0.9906218,0.0012439622,0.00032092535,0.0000061686155,0.0020318893,0.000004863002,0.00034093822,0.000032240376,0.002894049,0.000101605976],"about_ca_topic_score_codex":0.00019891137,"about_ca_topic_score_gemma":0.00011679045,"teacher_disagreement_score":0.060301024,"about_ca_system_score_codex":0.00006737656,"about_ca_system_score_gemma":0.000401062,"threshold_uncertainty_score":0.3737385},"labels":[],"label_agreement":null},{"id":"W4407406073","doi":"10.1080/23995270.2025.2466383","title":"Letter in reply: orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wilfrid Laurier University; Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Mathematics; Biology; Bioinformatics; Statistics","score_opus":0.013255557436094852,"score_gpt":0.22773559034760632,"score_spread":0.21448003291151146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8287176,0.02443658,0.000037526577,0.09103368,0.0018001238,0.0009991503,0.023751732,0.0000515418,0.029172055],"genre_scores_gemma":[0.95387137,0.00019977205,0.00002653052,0.0451395,0.00026276792,0.00008373153,0.00021466652,0.000010955645,0.00019073495],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988711,0.000028031454,0.00042003894,0.00039722383,0.000023268372,0.00026034666],"domain_scores_gemma":[0.999431,0.0001523036,0.000080369486,0.00022486398,0.00000983732,0.00010159642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012119683,0.00013948986,0.00030481914,0.00016162424,0.000042420965,0.00003676166,0.00013917651,0.000049365226,0.0017345761],"category_scores_gemma":[0.00006915155,0.00015737925,0.000053361397,0.0002068753,0.00004557552,0.000115087154,0.000053687974,0.00016254337,0.000022985028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012914273,0.00022129346,0.59320796,0.00017524419,0.00007103615,0.000019323146,0.00018780063,0.00006070543,0.0000023672492,0.14933422,0.2503234,0.006267482],"study_design_scores_gemma":[0.00052334525,0.000004174756,0.4583047,0.000016486996,0.000003920496,3.642345e-7,0.000055867873,0.0011772014,0.000004578924,0.022907123,0.5168571,0.00014517843],"about_ca_topic_score_codex":0.1097101,"about_ca_topic_score_gemma":0.15603107,"teacher_disagreement_score":0.26653367,"about_ca_system_score_codex":0.00051283085,"about_ca_system_score_gemma":0.00041399826,"threshold_uncertainty_score":0.999178},"labels":[],"label_agreement":null},{"id":"W4407710006","doi":"10.1080/23995270.2025.2466380","title":"Orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Business; Pharmacology; Mathematics; Statistics; Biology; Bioinformatics","score_opus":0.01286622521603255,"score_gpt":0.2277308317862886,"score_spread":0.21486460657025605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407710006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7413703,0.059730016,0.00012745682,0.043750517,0.003050843,0.0012703332,0.06779404,0.00010393106,0.08280256],"genre_scores_gemma":[0.9904802,0.00030107208,0.000032044296,0.008343544,0.00022447771,0.00006452736,0.00027058966,0.000010201113,0.00027333223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903023,0.000019902005,0.0003437374,0.0003458195,0.000022276932,0.00023804461],"domain_scores_gemma":[0.9994305,0.00014535694,0.00007824044,0.000198994,0.000013317929,0.00013361336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000083773375,0.00013578967,0.00028132214,0.000108294815,0.00006743259,0.000039859446,0.00014289346,0.000050658433,0.0027831087],"category_scores_gemma":[0.000060804156,0.00015155782,0.00005908792,0.00016768917,0.000048339025,0.00010136311,0.000052911957,0.00012364767,0.00003443984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009897644,0.00019893819,0.288751,0.00018158616,0.00012280536,0.000008272271,0.00013444136,0.00004087598,0.0000022095692,0.57574356,0.122128904,0.012588441],"study_design_scores_gemma":[0.0005204068,0.0000060307943,0.43725887,0.000013773377,0.0000083743225,5.1105644e-7,0.000121294805,0.001753134,0.000005073103,0.061959937,0.49817306,0.00017954333],"about_ca_topic_score_codex":0.082264505,"about_ca_topic_score_gemma":0.1004792,"teacher_disagreement_score":0.5137836,"about_ca_system_score_codex":0.00041029422,"about_ca_system_score_gemma":0.0005483784,"threshold_uncertainty_score":0.9981285},"labels":[],"label_agreement":null},{"id":"W4408500388","doi":"10.1080/23995270.2025.2466921","title":"Plain language summary of the outcomes from the first Rare Bone Disease Summit: current challenges and priority actions","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Summit; Current (fluid); Medicine; Disease; Intensive care medicine; Geography; Engineering; Internal medicine; Cartography","score_opus":0.009285446319931756,"score_gpt":0.25035602122044986,"score_spread":0.24107057490051811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408500388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67449695,0.31500834,0.0000044333756,0.0054847165,0.0008327176,0.00031821022,0.0037080303,0.000015717182,0.00013086028],"genre_scores_gemma":[0.98577106,0.012442853,0.000008248134,0.0005149151,0.00049814105,0.00005007653,0.00052151957,0.0000148181225,0.00017838381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990806,0.00008276767,0.00017857994,0.0003460115,0.00013717664,0.0001748652],"domain_scores_gemma":[0.9989702,0.000078417535,0.00008900746,0.0006800534,0.000057899193,0.00012443397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003899324,0.00020568063,0.0001891462,0.000025085708,0.00027559814,0.000030358293,0.00032268878,0.00007164796,0.000016677905],"category_scores_gemma":[0.00016373135,0.000120122844,0.00025443218,0.00007219276,0.00014275615,0.0000064645014,0.00032204067,0.000102026104,9.54252e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009034088,0.0012538328,0.7965169,0.00080870173,0.0009020336,0.00004993265,0.00092485716,0.000025777139,0.0011806682,0.001569946,0.12915577,0.0667082],"study_design_scores_gemma":[0.00041459556,0.000012981012,0.83110875,0.000093371396,0.00024608496,4.730655e-7,0.0018061887,0.000003677507,0.00023379188,0.00017772037,0.16575727,0.00014511883],"about_ca_topic_score_codex":0.00003213309,"about_ca_topic_score_gemma":0.0004761632,"teacher_disagreement_score":0.31127408,"about_ca_system_score_codex":0.000013116317,"about_ca_system_score_gemma":0.00018144578,"threshold_uncertainty_score":0.48984674},"labels":[],"label_agreement":null},{"id":"W4412069038","doi":"10.1080/23995270.2025.2515006","title":"Plain language summary: Patient journey and treatment patterns in progressive pulmonary fibrosis","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Pulmonary fibrosis; Medicine; Field (mathematics); Fibrosis; Intensive care medicine; Pathology; Mathematics","score_opus":0.004801572897415728,"score_gpt":0.2532780850455136,"score_spread":0.24847651214809785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412069038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512426,0.04259772,0.000004835604,0.0020335403,0.00037149803,0.0008839782,0.0014601487,0.000087895016,0.0013177415],"genre_scores_gemma":[0.9963521,0.0009613554,0.000045551045,0.0006664647,0.00051052554,0.00019546454,0.0007236538,0.000023005565,0.0005219012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874675,0.0000757677,0.0002676803,0.00040444138,0.00019046855,0.00031487667],"domain_scores_gemma":[0.9992883,0.000047608904,0.000067313784,0.0002821935,0.000049441234,0.00026512702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023125747,0.00027624506,0.0003824554,0.00021159451,0.00010291697,0.0000448043,0.00006844961,0.00010477904,0.00015220087],"category_scores_gemma":[0.000029348177,0.0002114143,0.00019034585,0.00020228619,0.000056454723,0.000112945985,0.000072461204,0.00012363438,0.0000045009224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015119511,0.003788566,0.72548723,0.0017485964,0.0004157696,0.014535974,0.0023067421,0.0000057760262,0.0006768844,0.0004922896,0.010217461,0.22520517],"study_design_scores_gemma":[0.0032881722,0.004262905,0.94057125,0.0057994267,0.0009375235,0.00020494258,0.014847288,0.0003338288,0.00049676775,0.00012878628,0.028507112,0.0006220223],"about_ca_topic_score_codex":0.00022586626,"about_ca_topic_score_gemma":0.000042328706,"teacher_disagreement_score":0.22458315,"about_ca_system_score_codex":0.00023235362,"about_ca_system_score_gemma":0.00018987093,"threshold_uncertainty_score":0.8621225},"labels":[],"label_agreement":null},{"id":"W4412676182","doi":"10.1080/23995270.2025.2535273","title":"A plain language summary of the phase 1/2 study of AAV5-hRKp.RPGR (botaretigene sparoparvovec) in people with RPGR-associated X-linked retinitis pigmentosa","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"Johnson and Johnson; Moorfields Eye Hospital NHS Foundation Trust; National Institute for Health and Care Research","keywords":"Retinitis pigmentosa; Phase (matter); Medicine; Physics; Ophthalmology","score_opus":0.0033371297559092344,"score_gpt":0.23963795153892645,"score_spread":0.2363008217830172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412676182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226224,0.0059783733,0.000021254682,0.0000907913,0.000157568,0.0006056519,0.00034383414,0.000014713749,0.0005255766],"genre_scores_gemma":[0.99847037,0.00026491503,0.00002232911,0.00010403281,0.000117019204,0.00007254088,0.00047258014,0.000022031796,0.00045416667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851114,0.00023579248,0.0003687996,0.0003778934,0.00026737904,0.000239004],"domain_scores_gemma":[0.9989788,0.000042675612,0.00023701298,0.0005474348,0.00013482981,0.000059236918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011336411,0.00022961618,0.0003542552,0.00007184571,0.000075944714,0.000015275122,0.00039729147,0.0001445438,0.00003336374],"category_scores_gemma":[0.00021199384,0.00016538953,0.00011965392,0.0005033865,0.00010389485,0.000006377465,0.00016018392,0.00013584888,3.466905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019494238,0.004871637,0.8540499,0.0005806972,0.0005157356,0.00008775006,0.0022305087,0.00012241451,0.12960894,0.00004481961,0.0039236057,0.0020145534],"study_design_scores_gemma":[0.017635785,0.0030649547,0.543299,0.0011122879,0.000798289,0.000009641984,0.03965623,0.000060020237,0.38991684,0.000071697454,0.003492433,0.00088279136],"about_ca_topic_score_codex":0.00015535028,"about_ca_topic_score_gemma":0.0009606266,"teacher_disagreement_score":0.31075087,"about_ca_system_score_codex":0.00003665727,"about_ca_system_score_gemma":0.00037417337,"threshold_uncertainty_score":0.67443895},"labels":[],"label_agreement":null},{"id":"W4413087173","doi":"10.1080/23995270.2025.2532358","title":"How I treat Rett syndrome with trofinetide: changes in dosing frequency and administration with rice cereal","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"ACADIA Pharmaceuticals","keywords":"Rett syndrome; Dosing; Administration (probate law); Medicine; Pharmacology; Biology; Biochemistry","score_opus":0.0037080078145349036,"score_gpt":0.20301450507727434,"score_spread":0.19930649726273944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413087173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937753,0.0034100595,0.000042776162,0.0020307298,0.000043550674,0.0002051798,0.00006425895,0.00001085668,0.0004172675],"genre_scores_gemma":[0.9981172,0.0005146421,0.00031185956,0.0002636951,0.000030919004,0.00004313529,0.0003051261,0.000013804994,0.00039962685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933577,0.000025638485,0.000067840876,0.00032845966,0.00008320164,0.00015907543],"domain_scores_gemma":[0.99971855,0.000005462699,0.000034977038,0.00015013147,0.000028780929,0.00006208625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000012912565,0.00016189196,0.00011672289,0.00005656696,0.00006251877,0.000057651083,0.00006747963,0.00006494449,0.0000032080213],"category_scores_gemma":[0.0000089005625,0.0001242496,0.000016925176,0.00014296915,0.00005120187,0.000005641278,0.000026524182,0.00004680072,1.672122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021219305,0.00055330055,0.7519497,0.0008691717,0.00023619205,0.00072637096,0.00023432168,0.000017590935,0.22172092,0.00037593502,0.0028402081,0.018354347],"study_design_scores_gemma":[0.0011027603,0.00080531527,0.9819856,0.00009226383,0.00005883902,0.00007005499,0.0005952517,0.0000025478805,0.013022155,0.000045275938,0.0019696676,0.00025025525],"about_ca_topic_score_codex":0.000013567021,"about_ca_topic_score_gemma":0.00096867146,"teacher_disagreement_score":0.2300359,"about_ca_system_score_codex":0.000010378283,"about_ca_system_score_gemma":0.00010983032,"threshold_uncertainty_score":0.5066751},"labels":[],"label_agreement":null},{"id":"W4415687071","doi":"10.1080/23995270.2025.2570636","title":"Plain Language Summary: kidney function and severe clinical events in people with Fabry disease who receive agalsidase beta","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"Sanofi","keywords":"Fabry disease; Renal function; BETA (programming language); Kidney disease; Disease","score_opus":0.008033434704794291,"score_gpt":0.2978692758426545,"score_spread":0.2898358411378602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415687071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980596,0.009777464,0.00004816316,0.0064945472,0.00027331064,0.0011174455,0.00054012774,0.00010328125,0.0010496778],"genre_scores_gemma":[0.9912482,0.00045668616,0.000032459488,0.002974788,0.00045466857,0.00011961275,0.0012683057,0.000036204,0.00340906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979762,0.00026422547,0.00031542193,0.0006072168,0.00045485303,0.00038208594],"domain_scores_gemma":[0.99829936,0.00018558094,0.00006680109,0.0004625933,0.00011744763,0.00086824095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015924909,0.00026517763,0.00048766125,0.00024140584,0.000122047975,0.000029978788,0.0001344123,0.00014408182,0.00025279922],"category_scores_gemma":[0.0006912129,0.00020648344,0.00013668762,0.00063405506,0.00009929228,0.00019463207,0.00012458401,0.00040077363,0.000015874368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067145387,0.00068666774,0.9398029,0.0007115215,0.0001549786,0.00047282752,0.00018720499,0.0000018553585,0.0000057274406,0.000088768116,0.037393086,0.013779926],"study_design_scores_gemma":[0.005120307,0.00025429472,0.98369384,0.0009669116,0.00033354713,0.0000070048,0.0017372855,0.00007072777,0.0000039208353,0.00013604785,0.0074542253,0.00022187168],"about_ca_topic_score_codex":0.00015829249,"about_ca_topic_score_gemma":0.0004623666,"teacher_disagreement_score":0.043890957,"about_ca_system_score_codex":0.00012456845,"about_ca_system_score_gemma":0.0007408815,"threshold_uncertainty_score":0.842015},"labels":[],"label_agreement":null},{"id":"W4417216476","doi":"10.1080/23995270.2025.2597031","title":"Real-world use of trofinetide: a survey of practices from prescribers at Rett syndrome centers of excellence in the United States","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Excellence; Rett syndrome; MEDLINE; CLARITY","score_opus":0.02088355461246003,"score_gpt":0.27030777140471646,"score_spread":0.24942421679225643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417216476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627674,0.0013849873,0.0000046573855,0.00021822871,0.000102831254,0.00022075025,0.0017369054,0.000002703788,0.000052221974],"genre_scores_gemma":[0.99361306,0.0033758502,0.00008740522,0.00016685054,0.000004787585,0.000011654698,0.0025800439,0.000009212888,0.00015115038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890953,0.00026390713,0.000304316,0.00024160634,0.00015290004,0.00012775189],"domain_scores_gemma":[0.99903214,0.00017343533,0.00031036395,0.00034818586,0.00010359311,0.0000322892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000826448,0.00012987485,0.00019033888,0.000104196006,0.000025132074,0.0000085491965,0.00026482722,0.000050330622,0.000015715459],"category_scores_gemma":[0.00023257035,0.00010234062,0.00006660511,0.00038963614,0.00010705424,0.000005577031,0.00012597365,0.000049251757,1.926667e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008614112,0.0003071026,0.9393605,0.00017379703,0.00012772159,0.000008895831,0.00021639712,0.0002964722,0.048365977,0.000009971582,0.010141277,0.00013050452],"study_design_scores_gemma":[0.00038245332,0.00009404105,0.9818906,0.00008276385,0.00004609274,4.8590965e-7,0.0004927597,0.000023397639,0.013251619,0.000014893,0.0036322419,0.00008864917],"about_ca_topic_score_codex":0.0071880566,"about_ca_topic_score_gemma":0.0054792957,"teacher_disagreement_score":0.04253013,"about_ca_system_score_codex":0.000008383222,"about_ca_system_score_gemma":0.00008659577,"threshold_uncertainty_score":0.99942315},"labels":[],"label_agreement":null},{"id":"W7110187874","doi":"10.1080/23995270.2025.2580913","title":"AIRLEAF <sup>®</sup> –a study of verducatib as a new kind of treatment for bronchiectasis: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Grifols; Vertex Pharmaceuticals; AstraZeneca; CSL Behring; Chiesi Farmaceutici; Sanofi; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Pfizer; Bundesministerium für Bildung und Forschung; Insmed; McGill University; Gilead Sciences; Boehringer Ingelheim","keywords":"Bronchiectasis; Exacerbation; Plain language; Placebo; Disease; Pill; Lung disease; Quality of life (healthcare)","score_opus":0.010421917389047939,"score_gpt":0.33273688081795516,"score_spread":0.3223149634289072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110187874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724507,0.022201998,0.000038470174,0.0009938764,0.00012923658,0.0027421382,0.0008479143,0.00005474488,0.0005409485],"genre_scores_gemma":[0.99431396,0.0001554002,0.00084204343,0.00013773445,0.00051463494,0.00029547996,0.0003854527,0.000029518122,0.0033257771],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99860156,0.00007631656,0.00034483962,0.00035825983,0.00033710885,0.00028192034],"domain_scores_gemma":[0.99846554,0.00043599927,0.00009981708,0.0005605631,0.00013209222,0.00030600853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050275015,0.00022660557,0.000591455,0.00024905958,0.00006129904,0.000012328031,0.00017068867,0.000058358968,0.00017937235],"category_scores_gemma":[0.0008436646,0.00017240239,0.00022872245,0.00038982977,0.00006514724,0.00007045689,0.00005838661,0.000077948534,0.0000040974573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03819638,0.024715206,0.15951514,0.0077978303,0.0051260404,0.00037953974,0.03981703,0.00048203548,0.0050562453,0.0007088178,0.3193217,0.39888403],"study_design_scores_gemma":[0.062749945,0.043342307,0.2698367,0.0051233717,0.006374483,0.000039808616,0.38853416,0.00055687845,0.013893118,0.0010003492,0.20749222,0.001056639],"about_ca_topic_score_codex":0.00083143596,"about_ca_topic_score_gemma":0.00021322999,"teacher_disagreement_score":0.3978274,"about_ca_system_score_codex":0.00020405985,"about_ca_system_score_gemma":0.0016399468,"threshold_uncertainty_score":0.70303655},"labels":[],"label_agreement":null},{"id":"W7117318193","doi":"10.1080/23995270.2025.2607961","title":"The plight of rare diseases in Southern Africa: health and social services policy recommendations","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aga Khan Foundation","funders":"","keywords":"Social Welfare; Health services; Social policy; Government (linguistics); Health policy; Public health","score_opus":0.004839057227458282,"score_gpt":0.2559353968020466,"score_spread":0.2510963395745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117318193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8339411,0.12685117,0.00001900406,0.029144865,0.0005689483,0.0006734967,0.008182962,0.000037639187,0.00058083615],"genre_scores_gemma":[0.99395156,0.0022910284,0.000021505808,0.0010789136,0.0005566585,0.000053280914,0.0014689168,0.000016610933,0.00056150695],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904037,0.00010251267,0.00024552093,0.00027794254,0.00008666448,0.0002470171],"domain_scores_gemma":[0.9994125,0.000031808926,0.000117025884,0.00024710238,0.00006988138,0.00012169223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042337255,0.00016119283,0.00018802486,0.00008579411,0.00035662777,0.000049312872,0.00022780248,0.00007300054,0.000007574101],"category_scores_gemma":[0.00003076138,0.00012046588,0.000119515156,0.00019204129,0.000094221956,0.000005459538,0.00016022162,0.000053737716,0.0000012011988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004004754,0.0036015452,0.46367,0.005918866,0.0016677296,0.000054736392,0.017551396,0.00006270021,0.004178933,0.03177336,0.25819936,0.20931663],"study_design_scores_gemma":[0.001923538,0.00020680827,0.13664469,0.00025052897,0.00015194766,0.00000411491,0.05886054,0.00002453448,0.00021397814,0.0036473032,0.79753083,0.0005412127],"about_ca_topic_score_codex":0.000091857844,"about_ca_topic_score_gemma":0.00035957954,"teacher_disagreement_score":0.53933144,"about_ca_system_score_codex":0.000023299925,"about_ca_system_score_gemma":0.00052137824,"threshold_uncertainty_score":0.4912456},"labels":[],"label_agreement":null}]}